Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 7/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | MGAM | O43451 | 2/20 | 0.50 |
| ▸ | SI | P14410 | 2/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | PRKCG | P05129 | 1/20 | 0.49 |
| ▸ | PRKCB | P05771 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11323167 | 0.75 | SRD5A1 (0.69) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL16124787 | 0.73 | MCL1 (0.54) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL15171956 | 0.72 | MCL1 (0.58) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL4658019 | 0.69 | GAA (0.75) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL668745 | 0.67 | GAA (0.61) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL30776763 | 0.67 | SRD5A1 (0.64) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL29363321 | 0.67 | GAA (0.61) | MCL1GAAMGAMSIMGAM2 | |
| Daphnetin SCHEMBL29612544 | 0.66 | MCL1 (1.00) | MCL1GAAMGAMSIMGAM2 | |
| Daphnetin SCHEMBL128212 | 0.66 | MCL1 (1.00) | MCL1GAAMGAMSIMGAM2 | |
| SCHEMBL15171965 | 0.66 | CA12 (0.63) | MCL1GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-16 | — | — | US | disclosed |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-02-16 | — | — | US | disclosed |
| EP-4017855-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2022-06-29 | — | — | EP | disclosed |
| CN-114206885-A | Pyrazolo [3,4-B ] pyrazine SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021149817-A1 | Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-07-29 | — | — | WO | disclosed |
| EP-3827009-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | Taiho Pharmaceutical Co., Ltd. (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| CN-112513050-A | Heterocyclic compounds inhibiting SHP2 activity | 大鹏药品工业株式会社 | 2021-03-16 | — | — | CN | disclosed |
| WO-2021033153-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-25 | — | — | WO | disclosed |
| EP-3759111-A1 | PHARMACEUTICAL COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111902415-A | Pharmaceutical compounds | 大冢制药株式会社 | 2020-11-06 | — | — | CN | disclosed |
| WO-2020022323-A1 | HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | MCL1 1360/4885GAA 878/4885MGAM 2409/4885 |
| US-20230146795-A1 | ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS | PTPN5, PTPN7, PTPN1 | MCL1 452/4885GAA 1969/4885MGAM 4285/4885 |
| US-20230049719-A1 | PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS | PTPN5, PTPRZ1, PTPN1 | MCL1 616/4885GAA 2268/4885MGAM 3714/4885 |
| US-12037345-B2 | Heterobicyclic compounds for inhibiting the activity of SHP2 | PTPN1, PTPN9, PTPN7 | MCL1 308/4885GAA 3440/4885MGAM 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.